Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection (Q43672287)

From Wikidata

Jump to navigation Jump to search

scientific article published in June 2001

Language	Label	Description	Also known as
English	Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection	scientific article published in June 2001

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

0 references

liver transplantation

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Rosenau J

1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Bahr MJ

2

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Tillmann HL

3

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Trautwein C

4

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Klempnauer J

5

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Manns MP

6

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Böker KHW

7

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

publication date

1 June 2001

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Journal of Hepatology

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

34

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

895-902

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Liver transplantation in European patients with the hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Liver transplantation and HBsAg-positive postnecrotic cirrhosis: adequate immunoprophylaxis and delta virus co-infection as the significant determinants of long-term prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine for hepatitis B in liver transplantation: a single-center experience

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine therapy for chronic hepatitis B: A six-month randomized dose- ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibodies against the GB virus C envelope 2 protein before liver transplantation protect against GB virus C de novo infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B and C coinfections and persistent hepatitis B infections: clinical outcome and liver pathology after transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Fulminant hepatitis B virus: recurrence after liver transplantation in two patients also infected with hepatitis delta virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Extension of transplantation free time by lamivudine in patients with hepatitis B-induced decompensated cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Adefovir dipivoxil

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0168-8278(01)00089-7

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43672287&oldid=2234134727"